The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies

The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies

Graphical Abstract Panel A. Primary endpoint of DELIVER [cardiovascular (CV) death or heart failure (HF) hospitalization] in the entire population (left) and in the population with LVEF 60. Panel B. A pooled analysis of patients enrolled in the DAPA-HF and DELIVER trials reveals a consistent benefit...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal Vol. 44; no. 5; pp. 342 - 344
Main Authors: de Boer, Rudolf A, Bauersachs, Johann
Format: Journal Article
Language:English
Published: England Oxford University Press 01-02-2023
Subjects:
Cardiomyopathies - complications
Heart Failure - therapy
Humans
Viewpoints
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Graphical Abstract Panel A. Primary endpoint of DELIVER [cardiovascular (CV) death or heart failure (HF) hospitalization] in the entire population (left) and in the population with LVEF 60. Panel B. A pooled analysis of patients enrolled in the DAPA-HF and DELIVER trials reveals a consistent benefit of dapagliflozin on the primary endpoint (CV death or HF hospitalization) across the entire spectrum of LVEF, with no signs of attenuation of the effect in the higher LVEF range. Panel C. Effect of acetazolamide on congestion in the ADVOR trial. From Day 1 onwards, the use of acetazolamide on top of regular loop diuretics resulted in accelerated decongestion. Panel D. KaplanMeier estimates of all-cause mortality or HF hospitalization for patients receiving PCI or optimal medical therapy in the REVIVED trial. LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conflict of interest: R.A.d.B. has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche. J.B. has received honoraria for lectures/consulting from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cardior, Corvia, CVRx, Novartis, Pfizer, Vifor and research support for the department from Zoll, CVRx, and Abiomed.
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehac781